Systemic lupus erythematosus and rheumatoid arthritis

Paper IV 
Paper V 
pre-patients controls 
patients 
HLA-SE 
50/90 (55.6) 
66/173 (38.2) 
423/735 (57.6) 
ACPA 
33/89 (37.1) 
5/353 (1.4) 
519/759 (68.4) 
IgA-RF 
25/59 (42.4) 
12/236 (5.1) 
- 
IgG-RF 
10/59 (16.9) 
10/236 (4.2) 
- 
IgM-RF 
13/59 (22.0) 
14/236 (5.9) 
568/760 (74.7) 
 
 
12. Functional study (paper V) 
For the functional study, individuals were sampled on the basis of carrying or 
not carrying the 
PTPN22
1858 T risk allele. Blood samples were collected from 
12 patients with RA, 12 SLE patients and 12 healthy controls. The patients were 
age and gender matched with the controls and within the patient groups the six 
PTPN22
1858 CC individuals were gender and age matched with the six 
PTPN22
1858 CT individuals. The blood samples were collected into 
Vacutainer cell preparation tubes (BD biosciences) and monocytes separated by 
centrifugation. T-lymphocytes were purified by immunodepletion of non-T-
cells using Pan T-cell isolation kit II human (Miltenyi Biotec). Cells were 
stimulated with 10 ng/ml phorbol 12-myristate, 13-acetate (PMA) plus 1 µM 
ionomycine; beads coated with monoclonal antibodies to CD3
ε
and CD28 
(Dynal Inc.); or with complete medium alone (RPMI 1640 + Glutamax and 10% 
heat inactivated FCS, 7.5% sodium bicarbonate, Penicillin / Streptavidin (10000 
u/ml / 10000 mg/ml), 100 mM sodium pyruvate and monothioglycerol). The 
cells were activated at a concentration of 10
6
cells/ml for 20h at 37
o
C (5% CO
2
). 
After activation, IL-2 concentration was measured in culture supernatants using 
Human IL-2 ELISA MAX Set Deluxe (BioLegend).